Sign up to save your podcasts
Or
Share EASL Studio Podcast: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
EASL Studio Podcast: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025?
What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?
Moderator: Ahmed Elsharkawy
Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens
This EASL Studio is supported by AbbVie. EASL has received no input from AbbVie with regards to the content of this programme.
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
View all episodes
By European Association for the Study of the Liver (EASL)What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?
Moderator: Ahmed Elsharkawy
Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens
This EASL Studio is supported by AbbVie. EASL has received no input from AbbVie with regards to the content of this programme.
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.